Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2268-2273

  Lebeau, Ilya ^a   Andrei, Graciela ^a   Krečmerová, Marcela ^b   De Clercq, Erik ^a   Holý, Antonin ^b   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 5 AZACYTOSINE; 2 PHOSPHONOMETHOXYETHYL DERIVATIVE; 2,4 DIAMINO 6 [2 (PHOSPHONOMETHOXY)ETHOXY]PYRIMIDINE; 3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL 5 AZACYTOSINE DERIVATIVE; 3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL DERIVATIVE; 6 [2 (PHOSPHONOMETHOXY)ALKOXY] 2,4 DIAMINOPYRIMIDINE DERIVATIVE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]ADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]3 DEAZAADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; [2,4 DIAMINO 3 HYDROXY 6 [2 (PHOSPHONOMETHOXY)PROPOXY]]PYRIMIDINE; CIDOFOVIR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COWPOX; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; SIMIAN VIRUS; VACCINIA; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYTOSINE; MICE; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; PHOSPHONIC ACIDS; POLYOMAVIRUS; PYRIMIDINE NUCLEOSIDES; PYRIMIDINES; SIMIAN VIRUS 40;

EID: 34250188092     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01422-06     Document Type: Article

References (24)

1. Andrei, G., R. Snoeck, M. Vandeputte, and E. De Clercq. 1997. Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. 41:587-593.
2. Balzarini, J., C. Pannecouque, L. Naesens, G. Andrei, R. Snoeck, E. De Clercq, D. Hockova, and A. Holy. 2004. 6-[2-(Phosphonomethoxy)alkoxy]-2,4- diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 23: 1321-1327.
3. Beadle, J. R., C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
4. De Clercq, E., G. Andrei, J. Balzarini, P. Leyssen, L. Naesens, J. Neyts, C. Pannecouque, R. Snoeck, C. Ying, D. Hockova, and A. Holy. 2005. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonornethoxy)alkoxy]-2,4-diarninopyrimidines. Nucleosides Nucleotides Nucleic Acids 24:331-341.
5. De Clercq, E., and A. Holy. 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4:928-940.
6. Gazdar, A. F., J. S. Butel, and M. Carbone. 2002. SV40 and human tumours: myth, association or causality? Nat. Rev. Cancer 2:957-964.
7. Hartline, C. B., K. M. Gustin, W. B. Wan, S. L. Ciesla, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2005. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis. 191:396-399.
8. Hockova, D., A. Holy, M. Masojidkova, G. Andrei, R. Snoeck, E. De Clercq, and J., Balzarini. 2004. Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg. Med. Chem. 12:3197-3202.
9. Hostetler, K. Y., S. Rought, K. A. Aldern, J. Trahan, J. R. Beadle, and J. Corbeil. 2006. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol. Cancer Ther. 5:156-159.
10. Josephson, M. A., J. W. Williams, A. Chandraker, and P. S. Randhawa. 2006. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl. Infect. Dis. 8:95-101.
11. Koralnik, I. J. 2004. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17:365-370.
12. Krecmerova, M., A. Holy, A. Piskala, M. Masojidkova, J. Balzarini, G. Andrei, R. Snoeck, L. Naesens, J. Neyts, and E. De Clercq. Acyclic nucleoside phosphonates with 5-azacytosine moiety: a new class of antiviral agents. In John Secrist III (ed.), Nucleosides, Nucleotides and Nucleic Acids, in press. Taylor and Francis, London, United Kingdom.
13. Krecmerova, M., A. Holy, A. Piskala, M. Masojidkova, G. Andrei, L. Naesens, J. Neyts, J. Balzarini, E. D. Clercq, and R. Snoeck. 2007. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2- (phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J. Med. Chem. 50:1069-1077.
14. Kuypers, D. R., A. K. Vandooren, E. Lerut, P. Evenepoel, K. Claes, R. Snoeck, L. Naesens, and Y. Vanrenterghem. 2005. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am. J. Transplant. 5:1997-2004.
15. Lebeau, I., G. Andrei, F. Dal Pozzo, J. R. Beadle, K. Y. Hostetler, E. De Clercq, O. J. Van Den, and R. Snoeck. 2006. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 50:2525-2529.
16. Lim, W. H., T. H. Mathew, J. E. Cooper, S. Bowden, and G. R. Russ. 2003. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology 8:318-323.
17. Osorio, S., R. de la Camara, N. Golbano, E. Marti, C. G. Fedele, S. Nieto, R. Manzanares, and J. M. Fernandez-Ranada. 2002. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant. 30:963-966.
18. Quenelle, D. C., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
19. Randhawa, P., N. A. Farasati, R. Shapiro, and K. Y. Hostetler. 2006. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob. Agents Chemother. 50:1564-1566.
20. Shitrit, D., N. Lev, A. Bar-Gil-Shitrit, and M. R. Kramer. 2005. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl. Int. 17: 658-665.
21. Vats, A., R. Shapiro, R. P. Singh, V. Scantlebury, A. Tuzuner, M. Saxena, M. L. Moritz, T. J. Beattie, T. Gonwa, M. D. Green, and D. Ellis. 2003. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75:105-112.
22. Viallard, J. F., E. Lazaro, M. E. Lafon, and J. L. Pellegrin. 2005. Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk. Lymphoma 46:1659-1662.
23. Wan, W. B., J. R. Beadle, C. Hartline, E. R. Kern, S. L. Ciesla, N. Valiaeva, and K. Y. Hostetler. 2005. Comparison of the antiviral activities of alkoxy-alkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 49:656-662.
24. White, M. K., and K. Khalili. 2004. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology 324: 1-16.